Leuprorelin - Tolmar

Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; LA 2575; Leuprogel®; SOT-375; SOU 375

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator QLT USA
  • Developer Tolmar
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Precocious puberty
  • Discontinued Endometriosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Sep 2015 Hospira has been acquired by Pfizer
  • 01 May 2015 Phase-III clinical trials in Precocious puberty (In children) in USA (SC) (NCT02452931)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top